Mega-Dose vitamin c joins fight against blood cancer
NCT ID NCT07177079
Summary
This early-stage study is testing whether adding very high doses of intravenous vitamin C to the standard two-drug treatment for acute myeloid leukemia (AML) is safe and more effective. It will enroll about 30 adults newly diagnosed with AML who are not healthy enough for intensive chemotherapy. The main goal is to find the safest dose of vitamin C to combine with the standard drugs and see if this combination helps more patients achieve remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Iowa Health Care
Iowa City, Iowa, 52242, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.